Multidrug-resistant tuberculosis is a special type of tuberculosis that is refractory to treatment, mainly because the patient’s body is infected with Mycobacterium tuberculosis and is resistant to common anti-tuberculosis drugs such as isoniazid and rifampin. So as you can see here, it is more difficult to treat because resistance to the most effective drugs has developed. In addition to rifampin and isoniazid, quinolone-resistant drugs, such as ofloxacin, plus four other drugs, such as kalamycin and butalacin, are also widely resistant. Extensive drug resistance is more serious, almost drug-free, and this is multidrug-resistant tuberculosis. The incidence of multidrug-resistant tuberculosis is generally about 10% of the general tuberculosis population, which means that about a quarter of patients who have relapsed without treatment in the past will develop multidrug-resistant tuberculosis. One, it is contagious for a longer period of time and can be easily transmitted to family members, colleagues, and close contacts of classmates. Second, the treatment time is very long, at least one and a half to two years. Third, the cost of treatment is more than 100 times that of ordinary tuberculosis. Fourth, the cure rate is low, with an average of only about 50% worldwide. After ten years of implementation in Wuhan, the cure rate has now reached 73%, which is higher than the global and national levels. It is not a high cure rate, so this is its main harm.